Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oglemilast in Allergen-induced Asthma
NCT00322686Phase 2Completed
- Sponsor
- Forest Laboratories
- Start
- May 2006
- Primary completion
- Dec 2006
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oglemilast in asthma (2 arms), sponsored by Forest Laboratories. Primary endpoint: Prevention of bronchoconstriction after allergen administration at 7 days. Started May 2006; status: completed.
02
Drugs
oglemilast
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00322686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322686.